Relief Therapeutics
About Relief Therapeutics
Relief Therapeutics aims to become a key player in the biotechnology and pharmaceutical industry.We will provide patients with therapeutic relief from diseases for which high needs persist.
We strongly believe that only by effectively treating patients will our investors realize significant return on investment.
Our areas of interest cover a broad range of indications from niche (orphan indications) up to larger markets.
Our experimental drugs are primarily of natural origin and have been already tested or used safely in the clinical setting thereby minimizing risks and maximizing efficacious potential.
Relief focuses on late stage clinical assets and strives to reduce development times and costs to quickly reach high quality decisive results.
YEAR FOUNDED:
1956
LEADERSHIP:
CEO: Raffaele Petrone
CFO: Tim Snyder
COO: Gael Hedou
CSO: Yves Sagot
Chief Business Officer: Michel Dreano
Chief Development Officer: Dorian Bevec
45 articles with Relief Therapeutics
-
CORRECTION: NeuroRx and Relief Announce Initial Successful Results from Expanded Access Use of RLF-100(TM) (aviptadil) in Patients with Critical COVID-19 and Severe Comorbidity: 72% Survival Seen in ICU Patients
11/25/2020
Correction of the press release published November 24, 2020: It has come to our attention that a mistake was printed in the percentage of control patients in the EAP who survived to day 28.
-
Relief Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG
11/23/2020
RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100TM in advanced clinical development to treat severe COVID-19 patients, gives notice of an Extraordinary General Meeting of shareholders to be held on December 17, 2020.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Relief Selects CRO and CDMO for RLF-100TM in Europe
11/18/2020
European clinical assessment of RLF-100(TM) for the treatment of COVID-19 induced lung injury planned to begin in Q1 2021
-
Relief, with Partner NeuroRx, Announces Enrollment of 150 Patients in Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure
11/13/2020
RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company") with its partner NeuroRx, Inc., announced that as of today, 150 patients (out of a targeted enrollment of 165) have been enrolled in the ongoing phase 2b/3 trial of RLF-100(TM) (aviptadil) for treating respiratory failure in patients with critical COVID-19.
-
NeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 with Respiratory Failure
11/13/2020
Observations of rapid recovery noted on chest x-ray and no drug-related Serious Adverse Events reported
-
BioSpace Movers & Shakers, Nov. 6
11/6/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
NeuroRx and Relief Therapeutics announce continuation of RLF-100™ trial for treatment of COVID-19 Respiratory Failure: Trial is on track to complete enrollment in 2020
11/5/2020
NeuroRx, Inc. and Relief Therapeutics Holdings AG announced that the independent Data Monitoring Committee met yesterday and voted unanimously that NCT 04311697 should continue as planned to its full enrollment of 165 patients.
-
Relief Appoints J. Paul Waymack, M.D., Sc.D. as Consultant to Strengthen Management Team
11/4/2020
RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100TM in advanced clinical development to treat severe COVID-19 patients, announced the appointment of J. Paul Waymack, M.D., Sc.D. as development and regulatory consultant.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 20, 2020.
-
BioSpace Global Roundup, Oct. 15
10/15/2020
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines. -
Relief Therapeutics and NeuroRx released results on Tuesday from their open-label prospective study looking into RLF-100 (aviptadil) as a potential treatment for COVID-19 and respiratory failure.
-
NeuroRx and Relief announce topline efficacy data from patients treated with RLF-100™ (aviptadil) under the U.S. FDA Expanded Access Protocol authorization for respiratory failure related to critical COVID-19
10/13/2020
RLF-100™ therapy associated with a 9-fold increased probability of survival and recovery from respiratory failure in an open-label, prospective study
-
BioSpace Movers & Shakers, Oct. 9
10/9/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Relief Therapeutics Appoints Industry Veteran, Jack Weinstein, as Chief Financial Officer and Treasurer
10/8/2020
RELIEF THERAPEUTICS Holding AG today announced the appointment of Jack Weinstein as Chief Financial Officer (CFO) and Treasurer, effective immediately.
-
BioSpace Global Roundup, Oct. 1
10/1/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business practices. -
NeuroRx and Relief Therapeutics Establish Supply and Distribution Agreements for RLF-100™ (aviptadil)
9/30/2020
Development partners establish supply chain agreements and order sufficient drug substance to treat 1 million patients
-
Relief Announces Capital Increase from its Final Tranche of the Share Subscription Facility with GEM
9/28/2020
Relief Announces Capital Increase from its Final Tranche of the Share Subscription Facility with GEM
-
BioSpace Global Roundup, Sept. 24
9/24/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses. -
Relief and NeuroRx Announce Partnership for Global Commercialization of RLF-100™ and Selection of Commercial Partners
9/21/2020
Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) has been reported under FDA Emergency Use IND authorization at multiple clinical sites